Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Milan Radovich, Patrick J. Kiel, Stacy M. Nance, Erin E. Niland, Megan E. Parsley, Meagan E. Ferguson, Guanglong Jiang, Natraj R. Ammakkanavar, Lawrence H. Einhorn, Liang Cheng, Mehdi Nassiri, Darrell D. Davidson, Daniel A. Rushing, Patrick J. Loehrer, Roberto Pili, Nasser Hanna, J. Thomas Callaghan, Todd C. Skaar, Paul R. Helft, Safi ShahdaBert H. O'Neil, Bryan P. Schneider

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Patients and methods: Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry for actionable targets. A multi-disciplinary tumor board reviewed all results. For each patient, the ratio of progression-free survival (PFS) of the genomically guided line of therapy divided by the PFS of their prior line was calculated. Patients whose PFS ratio was ≥ 1.3 were deemed to have a meaningful improvement in PFS. Results: From April 2014-October 2015, 168 patients were evaluated and 101 patients achieved adequate clinical follow-up for analysis. 19 of 44 (43.2%) patients treated with genomically guided therapy attained a PFS ratio ≥ 1.3 vs. 3 of 57 (5.3%) treated with non-genomically guided therapy (p < 0.0001). Similarly, overall PFS ratios (irrespective of cutoff) were higher for patients with genomically guided therapy vs non-genomically guided therapy (p = 0.05). Further, patients treated with genomically guided therapy had a superior median PFS compared to those treated with non-genomically guided therapy (86 days vs. 49 days, p = 0.005, H.R. = 0.55, 95% C.I.:0.37-0.84). Conclusion: Patients with refractory metastatic cancer who receive genomically guided therapy have improved PFS ratios and longer median PFS compared to patients who do not receive genomically guided therapy.

Original languageEnglish (US)
Pages (from-to)56491-56500
Number of pages10
JournalOncotarget
Volume7
Issue number35
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Genomics
  • Next-generation sequencing
  • Personalized medicine
  • Precision medicine

ASJC Scopus subject areas

  • Oncology

Cite this

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., Nassiri, M., Davidson, D. D., Rushing, D. A., Loehrer, P. J., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T. C., Helft, P. R., ... Schneider, B. P. (2016). Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget, 7(35), 56491-56500. https://doi.org/10.18632/oncotarget.10606